rejuvant life tabs

Easy-peasy Series-B(sy)

Latest articles

Can leucine turbo-charge longevity supplements and drugs?

Our exclusive interview with NuSirt’s founder explores how combining the sirtuin-activating amino acid has the potential to enhance the effect of longevity supplements and...

FOXO announces $10million investment to launch FOXO Life

FOXO Technologies Inc announces closing of $10 million investment to launch FOXO Life; continues commercialising epigenetic biomarker technology. FOXO Technologies Inc has announced that it...

Longevity supplements report: PDLH profile

The company behind Rejuvant, which partnered with the Buck Institute for Research on Aging on its calcium alpha-ketoglutarate longevity supplement. Over the coming weeks, we...

New research institute focuses on science of aging

New Bakar Aging Research Institute aims to drive deeply collaborative research to enhance translational medicine, progressing novel therapies from lab to clinic to community. UC...

Most read

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...
Supplement report

Editor's picks

Can leucine turbo-charge longevity supplements and drugs?

Our exclusive interview with NuSirt’s founder explores how combining the sirtuin-activating amino acid has the potential to enhance the effect of longevity supplements and...

FOXO announces $10million investment to launch FOXO Life

FOXO Technologies Inc announces closing of $10 million investment to launch FOXO Life; continues commercialising epigenetic biomarker technology. FOXO Technologies Inc has announced that it...

Longevity supplements report: PDLH profile

The company behind Rejuvant, which partnered with the Buck Institute for Research on Aging on its calcium alpha-ketoglutarate longevity supplement. Over the coming weeks, we...
Rejuvant

Nuritas launches PeptiYouth™ an AI-discovered peptide, clinically proven, anti-aging molecule.

Nuritas, a leader in Artificial Intelligence-based peptide discovery, has launched PeptiYouth™, a peptide discovered within peas and which, following clinical trials, has been shown to reduce cellular aging.

Longevity.Technology: We like peptides, as they’re generally recognised as safe (GRAS) and therefore accelerate through clinical pipelines quicker than some of their rejuvenation peers. This is an interesting validation of the approach; advanced cosmetics will be an area that we spend more time covering over the coming months.

Using their proprietary ground-breaking AI technology NπΦ (pronounced N-pi-fy or Nuritas Peptide Finder), Nuritas discovered and unlocked this peptide from the Pea Proteome. PeptiYouth has been clinically tested in a 40-person double blind placebo trial and shown to improve cellular regeneration. After 28 days of PeptiYouth use, human clinical trials showed a ‘significant’ reduction in wrinkle depth, reduction in skin roughness, reduction in skin inflammation and enhanced collagen production … and probably better than Zoom’s ‘touch up my appearance’.


 

“… the first of a suite of clinically tested ingredients Nuritas will be launching in the coming months.”

 


 

Back in October last year, when we asked Dr Nora Khaldi, Nuritas Founder and CEO about commercialisation of products she commented: “The one that’s on the market is an anti-inflammatory which was launched last year – the first AI discovered healthcare product in the consumer arena, PeptAIde is a post-exercise anti-inflammatory ingredient which contains a unique set of plant-based peptides that specifically help modulate inflammation. Our global partner on it is BASF. The next one is for skin anti-aging with the pre-diabetes coming next.

So the team has delivered on product 2 which is supported by peer-review: “The anti-ageing effects of a natural peptide discovered by Artificial Intelligence” in the International Journal of Cosmetic Science [1].

Elevant

“I am unbelievably proud of our team who worked tirelessly to make this happen. We have spent years refining our AI and machine learning platform in combination with our world class in-house laboratory and team of scientific experts. PeptiYouth is the first of a suite of clinically tested ingredients Nuritas™ will be launching in the coming months. This marks a step-change in the use of Peptides as active ingredients as well a massive step for the use of AI as a discovery tool augmenting human research capabilities ” commented Dr Nora Khaldi, Nuritas Founder and CEO.

U2’s The Edge visits the Nuritas team at their Dublin headquarters.

Elevant

U2 are on Nuritas’ list of high-profile investors and Khaldi told us last year that 2020 is when the company will be looking for Series B funding – this current traction will no doubt help the company’s valuation.

[1] onlinelibrary.wiley.com/…0.1111/ics.12635

Image courtesy of Nuritas Limited
Phil Newman
Editor-in-Chief Phil is Editor-in-Chief Longevity.Technology and founder of First Longevity which brings together international investors and Longevity start-ups.

In his career, Phil has held c-level management positions; applying his marketing and business development expertise into these tech sectors: Longevity; IoT; AI; Medical Devices; Biopharma; 3D Manufacturing; Smartgrid and Sustainability.
Rejuvant

Most popular

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...

Is nicotinamide riboside a safe and effective way to combat aging?

ChromaDex executive highlights the importance of clinical studies to prove the benefits of NAD+ boosting compound. ChromaDex is the company behind the popular healthy aging...
Supplement report

Related articles

Can leucine turbo-charge longevity supplements and drugs?

Our exclusive interview with NuSirt’s founder explores how combining the sirtuin-activating amino acid has the potential to enhance the effect of longevity supplements and...

Targeting mitochondria to beat hair loss and skin wrinkles

Yuva Biosciences gears up for human trials of cosmeceutical treatments that target mitochondrial dysfunction. With an initial focus on developing cosmeceuticals, US start-up Yuva Biosciences...

HitGen and BioAge progress drug discovery collaboration

Companies announce research progress in DNA-encoded library-based drug discovery research collaboration. Shanghai Stock Exchange-listed biotech HitGen, Inc announced important research progress in a collaboration with...

New investor offers funding to healthy aging innovators

A fifth investor has joined UK Research and Innovation (UKRI), providing matched funding for top small innovators to develop ideas for healthy aging. The new...

Nerve regeneration tech targets Alzheimer’s and Nasdaq

NervGen readies for NASDAQ listing and clinical trials of lead compound for nerve regeneration in 2021. With a unique nerve regeneration technology, Canadian biotech NervGen...
Supps report ad middle